Orion Infusions (DHA:ORIONINFU) Other Long-Term Liabilities: BDT20.4 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ORIONINFU Orion Infusions Ltd DHA:ORIONINFU
70 GF Score
Price BDT188.60
GF Value BDT312.59
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Orion Infusions Other Long-Term Liabilities?

Orion Infusions DHA:ORIONINFU -3.48% 70 Other Long-Term Liabilities is BDT20.4 Mil as of Mar. 2026. GuruFocus rates DHA:ORIONINFU with a GF Score™ of 70/100 and a GF Value™ of BDT312.59 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Orion Infusions's other long-term liabilities for the quarter that ended in Mar. 2026 was BDT20.4 Mil.

Orion Infusions's quarterly other long-term liabilities declined from Sep. 2025 (BDT20.3 Mil) to Dec. 2025 (BDT20.2 Mil) but then increased from Dec. 2025 (BDT20.2 Mil) to Mar. 2026 (BDT20.4 Mil).

Orion Infusions's annual other long-term liabilities declined from Jun. 2023 (BDT21.7 Mil) to Jun. 2024 (BDT19.6 Mil) but then increased from Jun. 2024 (BDT19.6 Mil) to Jun. 2025 (BDT20.3 Mil).

Orion Infusions Other Long-Term Liabilities Related Terms

Orion Infusions Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Orion Infusions's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Infusions Other Long-Term Liabilities Chart

Orion Infusions Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.03 22.04 21.73 19.59 20.25

Orion Infusions Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.81 20.25 20.31 20.23 20.38
DHA:ORIONINFU
70GF Score
Orion Infusions Ltd DHA:ORIONINFU
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orion Infusions Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of BDT20.4 Mil mean?
Orion Infusions (DHA:ORIONINFU) has a Other Long-Term Liabilities of BDT20.4 Mil as of Mar. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Orion Infusions and its competitors.
Is Orion Infusions' Other Long-Term Liabilities too high?
Orion Infusions' current Other Long-Term Liabilities is BDT20.4 Mil. Overall, Orion Infusions has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orion Infusions' Other Long-Term Liabilities compare to ZTS and UTHR?
Orion Infusions' Other Long-Term Liabilities of BDT20.4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Orion Infusions and its competitors. Orion Infusions's current Other Long-Term Liabilities is BDT20.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Infusions stock overvalued right now?
Based on GuruFocus' analysis, Orion Infusions (DHA:ORIONINFU) is currently considered Significantly Undervalued. The stock's GF Value™ is BDT312.59, compared to a current price of BDT188.60 — trading 39.7% below its estimated fair value. The current Other Long-Term Liabilities is BDT20.4 Mil. Orion Infusions' overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Orion Infusions (DHA:ORIONINFU), the current Other Long-Term Liabilities is BDT20.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Infusions (DHA:ORIONINFU) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Infusions stock appears to be undervalued. The current stock price of BDT188.60 is trading 39.7% below its estimated GF Value™ of BDT312.59. GuruFocus considers Orion Infusions to be Significantly Undervalued.

Key valuation signals for DHA:ORIONINFU:

  • Other Long-Term Liabilities: BDT20.4 Mil
  • GF Value™: BDT312.59 vs. price of BDT188.60 (39.7% below fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the DHA:ORIONINFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orion Infusions Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Infusions Ltd is a pharmaceutical company engaged in the production of various types of intravenous fluids, rehydration solutions, electrolyte solutions, and solutions for acidosis, as well as Ranitidine I.V. infusion and anti-microbial products such as Ciprofloxacin I.V. and Metronidazole I.V. The Company's products include Dextrolac, Dextropac, Dextrosal, Dianak, Electro Dex, Fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the Group operates across several sectors, including pharma and healthcare, power and energy, infrastructure development, real estate, cosmetics and toiletries, consumer products, textiles and garments, and home appliances. Geographically, the Company operates in Bangladesh.
70GF Score

Get the complete analysis for DHA:ORIONINFU

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT188.60
Price
BDT312.59
GF Value